Moderna, Inc. — Director's Dealing 2021

Mar 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2021-03-22

Reporting Person: Zaks Tal Zvi (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-22	Common Stock	M	1199	$20.93	Acquired	1199	Direct
2021-03-22	Common Stock	S	255	$142.83	Disposed	944	Direct
2021-03-22	Common Stock	S	366	$144.06	Disposed	578	Direct
2021-03-22	Common Stock	S	227	$145.47	Disposed	351	Direct
2021-03-22	Common Stock	S	290	$146.46	Disposed	61	Direct
2021-03-22	Common Stock	S	61	$147.50	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-22	Stock Option (Right to Buy)	$20.93	M	1199	Disposed	2029-03-08	Common Stock (1199)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $142.23 to $143.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $143.63 to $144.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $144.89 to $145.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $146.15 to $146.95. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F6: 25% of this option vested and became exercisable on March 8, 2020 with the remainder vesting in 12 equal quarterly installments thereafter.